Literature DB >> 23024024

Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease.

Patrick Mallia1, Joseph Footitt, Rosa Sotero, Annette Jepson, Marco Contoli, Maria-Belen Trujillo-Torralbo, Tatiana Kebadze, Julia Aniscenko, Gregory Oleszkiewicz, Katrina Gray, Simon D Message, Kazuhiro Ito, Peter J Barnes, Ian M Adcock, Alberto Papi, Luminita A Stanciu, Sarah L Elkin, Onn M Kon, Malcolm Johnson, Sebastian L Johnston.   

Abstract

RATIONALE: Chronic obstructive pulmonary disease (COPD) exacerbations are associated with virus (mostly rhinovirus) and bacterial infections, but it is not known whether rhinovirus infections precipitate secondary bacterial infections.
OBJECTIVES: To investigate relationships between rhinovirus infection and bacterial infection and the role of antimicrobial peptides in COPD exacerbations.
METHODS: We infected subjects with moderate COPD and smokers and nonsmokers with normal lung function with rhinovirus. Induced sputum was collected before and repeatedly after rhinovirus infection and virus and bacterial loads measured with quantitative polymerase chain reaction and culture. The antimicrobial peptides secretory leukoprotease inhibitor (SLPI), elafin, pentraxin, LL-37, α-defensins and β-defensin-2, and the protease neutrophil elastase were measured in sputum supernatants.
MEASUREMENTS AND MAIN RESULTS: After rhinovirus infection, secondary bacterial infection was detected in 60% of subjects with COPD, 9.5% of smokers, and 10% of nonsmokers (P < 0.001). Sputum virus load peaked on Days 5-9 and bacterial load on Day 15. Sputum neutrophil elastase was significantly increased and SLPI and elafin significantly reduced after rhinovirus infection exclusively in subjects with COPD with secondary bacterial infections, and SLPI and elafin levels correlated inversely with bacterial load.
CONCLUSIONS: Rhinovirus infections are frequently followed by secondary bacterial infections in COPD and cleavage of the antimicrobial peptides SLPI and elafin by virus-induced neutrophil elastase may precipitate these secondary bacterial infections. Therapy targeting neutrophil elastase or enhancing innate immunity may be useful novel therapies for prevention of secondary bacterial infections in virus-induced COPD exacerbations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23024024      PMCID: PMC3530206          DOI: 10.1164/rccm.201205-0806OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  32 in total

Review 1.  Safety of sputum induction.

Authors:  E Pizzichini; M M M Pizzichini; R Leigh; R Djukanović; P J Sterk
Journal:  Eur Respir J Suppl       Date:  2002-09

2.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

Authors:  T A Seemungal; G C Donaldson; E A Paul; J C Bestall; D J Jeffries; J A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  1998-05       Impact factor: 21.405

3.  Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease.

Authors:  R Zalacain; V Sobradillo; J Amilibia; J Barrón; V Achótegui; J I Pijoan; J L Llorente
Journal:  Eur Respir J       Date:  1999-02       Impact factor: 16.671

4.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Authors:  G C Donaldson; T A R Seemungal; A Bhowmik; J A Wedzicha
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

5.  Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations.

Authors:  Alberto Papi; Cinzia Maria Bellettato; Fausto Braccioni; Micaela Romagnoli; Paolo Casolari; Gaetano Caramori; Leonardo M Fabbri; Sebastian L Johnston
Journal:  Am J Respir Crit Care Med       Date:  2006-02-16       Impact factor: 21.405

6.  Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages.

Authors:  B G G Oliver; S Lim; P Wark; V Laza-Stanca; N King; J L Black; J K Burgess; M Roth; S L Johnston
Journal:  Thorax       Date:  2008-02-01       Impact factor: 9.139

7.  An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study.

Authors:  Patrick Mallia; Simon D Message; Tatiana Kebadze; Hayley L Parker; Onn M Kon; Sebastian L Johnston
Journal:  Respir Res       Date:  2006-09-06

8.  Projections of global mortality and burden of disease from 2002 to 2030.

Authors:  Colin D Mathers; Dejan Loncar
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

Review 9.  Chronic obstructive pulmonary disease.

Authors:  Marc Decramer; Wim Janssens; Marc Miravitlles
Journal:  Lancet       Date:  2012-02-06       Impact factor: 79.321

10.  Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation.

Authors:  Robert J Cameron; Deo de Wit; Toni N Welsh; John Ferguson; Terry V Grissell; Peter J Rye
Journal:  Intensive Care Med       Date:  2006-05-24       Impact factor: 17.440

View more
  105 in total

1.  Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease.

Authors:  Gavin C Donaldson; Martin Law; Beverly Kowlessar; Richa Singh; Simon E Brill; James P Allinson; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2015-10-15       Impact factor: 21.405

Review 2.  Antimicrobial host defence peptides: functions and clinical potential.

Authors:  Neeloffer Mookherjee; Marilyn A Anderson; Henk P Haagsman; Donald J Davidson
Journal:  Nat Rev Drug Discov       Date:  2020-02-27       Impact factor: 84.694

3.  Lung allograft donors with excessive alcohol use have increased levels of human antimicrobial peptide LL-37.

Authors:  M Camargo Moreno; J B Lewis; E J Kovacs; E M Lowery
Journal:  Alcohol       Date:  2018-11-09       Impact factor: 2.405

4.  What doesn't kill you makes you weaker.

Authors:  S Vamsee Raju
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-11-06       Impact factor: 5.464

5.  Experimental Human Pneumococcal Colonization in Older Adults Is Feasible and Safe, Not Immunogenic.

Authors:  Hugh Adler; Esther L German; Elena Mitsi; Elissavet Nikolaou; Sherin Pojar; Caz Hales; Rachel Robinson; Victoria Connor; Helen Hill; Angela D Hyder-Wright; Lepa Lazarova; Catherine Lowe; Emma L Smith; India Wheeler; Seher R Zaidi; Simon P Jochems; Dessi Loukov; Jesús Reiné; Carla Solórzano-Gonzalez; Polly de Gorguette d'Argoeuves; Tessa Jones; David Goldblatt; Tao Chen; Stephen J Aston; Neil French; Andrea M Collins; Stephen B Gordon; Daniela M Ferreira; Jamie Rylance
Journal:  Am J Respir Crit Care Med       Date:  2021-03-01       Impact factor: 21.405

Review 6.  Innate immunity and chronic obstructive pulmonary disease: a mini-review.

Authors:  Renat Shaykhiev; Ronald G Crystal
Journal:  Gerontology       Date:  2013-09-03       Impact factor: 5.140

7.  Regulation and activity of secretory leukoprotease inhibitor (SLPI) is altered in smokers.

Authors:  Megan Meyer; Rebecca N Bauer; Blanche D Letang; Luisa Brighton; Elizabeth Thompson; Rosalia C M Simmen; James Bonner; Ilona Jaspers
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-27       Impact factor: 5.464

Review 8.  The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma.

Authors:  Richard Hewitt; Hugo Farne; Andrew Ritchie; Emma Luke; Sebastian L Johnston; Patrick Mallia
Journal:  Ther Adv Respir Dis       Date:  2015-11-26       Impact factor: 4.031

9.  Hospitalizations and outpatient visits for rhinovirus-associated acute respiratory illness in adults.

Authors:  E Kathryn Miller; Jodell Linder; David Kraft; Monika Johnson; Pengcheng Lu; Benjamin R Saville; John V Williams; Marie R Griffin; H Keipp Talbot
Journal:  J Allergy Clin Immunol       Date:  2015-08-06       Impact factor: 10.793

10.  Nasopharyngeal Proteobacteria are associated with viral etiology and acute wheezing in children with severe bronchiolitis.

Authors:  Embriette R Hyde; Joseph F Petrosino; Pedro A Piedra; Carlos A Camargo; Janice A Espinola; Jonathan M Mansbach
Journal:  J Allergy Clin Immunol       Date:  2013-12-22       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.